![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NEW MEDRAD 3.0T PROSTATE ECOIL ENABLES PERSONALIZED TREATMENT PLANNING
NEW MEDRAD 3.0T PROSTATE ECOIL ENABLES PERSONALIZED TREATMENT PLANNING
August 3, 2006
Patients diagnosed with prostate cancer often undergo either a radical prostatectomy, complete removal of the prostate gland, or radiation treatment over large portions of the prostate to combat the cancer. The after-effects on the patient can include impotence, urinary incontinence, and bleeding. MEDRAD designed the 3.0T Prostate
eCoil to produce very accurate diagnostic images of the prostate that may enable
early diagnosis and staging of prostate cancer. The 3.0T Prostate eCoil can
also be used to plan radiation therapy in a way that helps physicians localize
treatment to only the affected part of the gland. By giving clinicians more
accurate images for use in planning and delivering targeted treatment, the eCoil
may help them personalize the patient's treatment.
PR
Newswire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct